201 related articles for article (PubMed ID: 28360099)
21. Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from
Sahuc ME; Sahli R; Rivière C; Pène V; Lavie M; Vandeputte A; Brodin P; Rosenberg AR; Dubuisson J; Ksouri R; Rouillé Y; Sahpaz S; Séron K
J Virol; 2019 May; 93(10):. PubMed ID: 30842319
[TBL] [Abstract][Full Text] [Related]
22. Identification of serotonin 2A receptor as a novel HCV entry factor by a chemical biology strategy.
Cao L; Chen J; Wang Y; Yang Y; Qing J; Rao Z; Chen X; Lou Z
Protein Cell; 2019 Mar; 10(3):178-195. PubMed ID: 29542010
[TBL] [Abstract][Full Text] [Related]
23. A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo.
Meuleman P; Catanese MT; Verhoye L; Desombere I; Farhoudi A; Jones CT; Sheahan T; Grzyb K; Cortese R; Rice CM; Leroux-Roels G; Nicosia A
Hepatology; 2012 Feb; 55(2):364-72. PubMed ID: 21953761
[TBL] [Abstract][Full Text] [Related]
24. Infection with hepatitis C virus depends on TACSTD2, a regulator of claudin-1 and occludin highly downregulated in hepatocellular carcinoma.
Sekhar V; Pollicino T; Diaz G; Engle RE; Alayli F; Melis M; Kabat J; Tice A; Pomerenke A; Altan-Bonnet N; Zamboni F; Lusso P; Emerson SU; Farci P
PLoS Pathog; 2018 Mar; 14(3):e1006916. PubMed ID: 29538454
[TBL] [Abstract][Full Text] [Related]
25. Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry.
Riva L; Song OR; Prentoe J; Helle F; L'homme L; Gattolliat CH; Vandeputte A; Fénéant L; Belouzard S; Baumert TF; Asselah T; Bukh J; Brodin P; Cocquerel L; Rouillé Y; Dubuisson J
J Virol; 2018 May; 92(10):. PubMed ID: 29491159
[TBL] [Abstract][Full Text] [Related]
26. [Claudin 1 as a target for anti-hepatitis C virus strategy].
Fukasawa M
Yakugaku Zasshi; 2014; 134(5):635-40. PubMed ID: 24790046
[TBL] [Abstract][Full Text] [Related]
27. Antibody targeting of claudin-1 as a potential colorectal cancer therapy.
Cherradi S; Ayrolles-Torro A; Vezzo-Vié N; Gueguinou N; Denis V; Combes E; Boissière F; Busson M; Canterel-Thouennon L; Mollevi C; Pugnière M; Bibeau F; Ychou M; Martineau P; Gongora C; Del Rio M
J Exp Clin Cancer Res; 2017 Jun; 36(1):89. PubMed ID: 28659146
[TBL] [Abstract][Full Text] [Related]
28. Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice.
Vercauteren K; Brown RJ; Mesalam AA; Doerrbecker J; Bhuju S; Geffers R; Van Den Eede N; McClure CP; Troise F; Verhoye L; Baumert T; Farhoudi A; Cortese R; Ball JK; Leroux-Roels G; Pietschmann T; Nicosia A; Meuleman P
Gut; 2016 Dec; 65(12):2029-2034. PubMed ID: 26306759
[TBL] [Abstract][Full Text] [Related]
29. Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells.
Anggakusuma ; Colpitts CC; Schang LM; Rachmawati H; Frentzen A; Pfaender S; Behrendt P; Brown RJ; Bankwitz D; Steinmann J; Ott M; Meuleman P; Rice CM; Ploss A; Pietschmann T; Steinmann E
Gut; 2014 Jul; 63(7):1137-49. PubMed ID: 23903236
[TBL] [Abstract][Full Text] [Related]
30. Correlation of the tight junction-like distribution of Claudin-1 to the cellular tropism of hepatitis C virus.
Yang W; Qiu C; Biswas N; Jin J; Watkins SC; Montelaro RC; Coyne CB; Wang T
J Biol Chem; 2008 Mar; 283(13):8643-53. PubMed ID: 18211898
[TBL] [Abstract][Full Text] [Related]
31. Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry.
Lin LT; Chung CY; Hsu WC; Chang SP; Hung TC; Shields J; Russell RS; Lin CC; Li CF; Yen MH; Tyrrell DL; Lin CC; Richardson CD
J Hepatol; 2015 Mar; 62(3):541-8. PubMed ID: 25450204
[TBL] [Abstract][Full Text] [Related]
32. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry.
Evans MJ; von Hahn T; Tscherne DM; Syder AJ; Panis M; Wölk B; Hatziioannou T; McKeating JA; Bieniasz PD; Rice CM
Nature; 2007 Apr; 446(7137):801-5. PubMed ID: 17325668
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis C virus receptor expression in normal and diseased liver tissue.
Reynolds GM; Harris HJ; Jennings A; Hu K; Grove J; Lalor PF; Adams DH; Balfe P; Hübscher SG; McKeating JA
Hepatology; 2008 Feb; 47(2):418-27. PubMed ID: 18085708
[TBL] [Abstract][Full Text] [Related]
34. Berberine inhibits hepatitis C virus entry by targeting the viral E2 glycoprotein.
Hung TC; Jassey A; Liu CH; Lin CJ; Lin CC; Wong SH; Wang JY; Yen MH; Lin LT
Phytomedicine; 2019 Feb; 53():62-69. PubMed ID: 30668413
[TBL] [Abstract][Full Text] [Related]
35. Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus.
Vausselin T; Séron K; Lavie M; Mesalam AA; Lemasson M; Belouzard S; Fénéant L; Danneels A; Rouillé Y; Cocquerel L; Foquet L; Rosenberg AR; Wychowski C; Meuleman P; Melnyk P; Dubuisson J
J Virol; 2016 Oct; 90(19):8422-34. PubMed ID: 27412600
[TBL] [Abstract][Full Text] [Related]
36. Pentagalloylglucose, a highly bioavailable polyphenolic compound present in Cortex moutan, efficiently blocks hepatitis C virus entry.
Behrendt P; Perin P; Menzel N; Banda D; Pfaender S; Alves MP; Thiel V; Meuleman P; Colpitts CC; Schang LM; Vondran FWR; Anggakusuma ; Manns MP; Steinmann E; Pietschmann T
Antiviral Res; 2017 Nov; 147():19-28. PubMed ID: 28923507
[TBL] [Abstract][Full Text] [Related]
37. Hepatitis C virus entry is impaired by claudin-1 downregulation in diacylglycerol acyltransferase-1-deficient cells.
Sung PS; Murayama A; Kang W; Kim MS; Yoon SK; Fukasawa M; Kondoh M; Kim JS; Kim H; Kato T; Shin EC
J Virol; 2014 Aug; 88(16):9233-44. PubMed ID: 24899196
[TBL] [Abstract][Full Text] [Related]
38. Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice.
Lacek K; Vercauteren K; Grzyb K; Naddeo M; Verhoye L; Słowikowski MP; Fafi-Kremer S; Patel AH; Baumert TF; Folgori A; Leroux-Roels G; Cortese R; Meuleman P; Nicosia A
J Hepatol; 2012 Jul; 57(1):17-23. PubMed ID: 22414763
[TBL] [Abstract][Full Text] [Related]
39. Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro.
Fénéant L; Ghosn J; Fouquet B; Helle F; Belouzard S; Vausselin T; Séron K; Delfraissy JF; Dubuisson J; Misrahi M; Cocquerel L
PLoS One; 2015; 10(11):e0142539. PubMed ID: 26561856
[TBL] [Abstract][Full Text] [Related]
40. Characterisation of endogenous Claudin-1 expression, motility and susceptibility to hepatitis C virus in CRISPR knock-in cells.
Clément CMH; Deffieu MS; Dorobantu CM; Baumert TF; Ayala-Nunez NV; Mély Y; Ronde P; Gaudin R
Biol Cell; 2020 May; 112(5):140-151. PubMed ID: 32034780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
